Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches

Current Drug Metabolism

Volumn 10, Issue 10, 2009, Pages 1066-1074

  Belǐ, Alě ^a   Temesv́ri, Manna ^b   Kohalmy, Krisztina ^b   Vrzal, Radim ^c   Dvorak, Zdenek ^c   Rozman, Damjana ^a   Monostory, Katalin ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b CHEMICAL RESEARCH CENTER   (Hungary)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CYP2C9; Dehydroepiandrosterone; Dexamethasone; Dynamical systems; Estrogen receptor; Mathematical modelling; Nuclear receptors; Simulation

Indexed keywords

CYTOCHROME P450 2C9; DEXAMETHASONE; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PRASTERONE; PREGNANE X RECEPTOR; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ENZYME INDUCTION; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; HOMEOSTASIS; HUMAN; LIVER CELL; MATHEMATICAL MODEL; MOLECULAR MECHANICS; PROTEIN FUNCTION; REVIEW; SIMULATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; CHEMICAL MODEL; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; PROCEDURES;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CYTOCHROME P-450 CYP2C9; DEHYDROEPIANDROSTERONE; ENZYME INDUCTION; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL;

EID: 77649173151     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790820147     Document Type: Review

References (37)

1. Lewis, D.F.V. In: Guide to Cytochromes P450: Structure and Function Substrate selectivity and metabolism; Lewis, D.F.V., Ed.; Taylor&Francis: London, 2001; pp. 76-117.
2. Iyanagi, T. Molecular mechanism of phase I and phase II drugmetabolizing enzymes: implications for detoxifications. Int. Rev. Cytol., 2007, 260, 35-112.
3. Guengerich, F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8, E101-E111.
4. Cellier, F.E. Continuous System Modelling; Springer-Verlag: New York, 1991.
5. Matko, D.; Karba, R.; Zupaňǐ, B. Simulation and Modelling of Continuous Systems: A Case Study Approach; Prentice Hall: New York, 1992.
6. Ljung, L. System Identification - Theory for the User, 2nd ed.; Prentice-Hall: London, 1999.
7. Hopensteadt, C.H.; Peskin, C.S. Modeling and Simulation in Medicine and the Life Sciences; Springer: New York, 2002.
8. Ferguson, S.S.; LeCluyse, E.L.; Negishi, M.; Goldstein, J.A. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol. Pharmacol., 2002, 62, 737-746.
9. Ferguson, S.S.; Chen, Y.; LeCluyse, E.L.; Negishi, M.; Goldstein, J.A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol., 2005, 68, 747-757.
10. Gerbal-Chaloin, S.; Pascussi, J.-M.; Pichard-Garcia, L.; Daujat, M.; Waechter, F.; Fabre, J.-M.; Carrere, N.; Maurel, P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos., 2001, 29, 242-251.
11. Gerbal-Chaloin, S.; Daujat, M.; Pascussi, J.-M.; Pichard-Garcia, L.; Vilarem, M.-J.; Maurel, P. Transcriptional regulation of CYP2C9 gene. J. Biol. Chem., 2002, 277, 209-217.
12. Pascussi, J.-M.; Gerbal-Chaloin, S.; Fabre, J.-M.; Maurel, P.; Vilarem, M.-J. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol. Pharmacol., 2000, 58, 1441-1450.
13. Lehmann, J.M.; McKee, D.D.; Watson, M.A.; Willson, T.M.; Moore, J.T.; Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 1998, 102, 1016-1023.
14. Onica, T.; Nichols, K.; Larin, M.; Ng, L.; Maslen, A.; Dvorak, Z.; Pascussi, J.-M.; Vilarem, M.-J.; Maurel, P.; Kirby, G.M. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4α to the proximal promoter. Mol. Pharmacol., 2008, 73, 451-460.
15. Ringel, M.; Oesch, F.; Gerl, M.; Klebach, M.; Quint, M.; Bader, A.; Böttger, T.; Hengstler, J.G. Permissive and suppressive effects of dexamethasone on enzyme induction in hepatocyte co-cultures. Xenobiotica, 2002, 32, 653-666.
16. Pascussi, J.-M.; Drocourt, L.; Fabre, J.-M.; Maurel, P.; Vilarem, M.-J. Dexamethasone induces pregnane X receptor and retinoid X receptor-a expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol., 2000, 58, 361-372.
17. LAω) by dehydroepiandrosterone in rats: a possible peroxisomal proliferators. Cancer Res., 1989, 49, 2337-2343.
18. Miller, W.L. Androgen biosynthesis from cholesterol to DHEA. Mol. Cell Endocrinol., 2002, 198, 7-14.
19. Labrie, F.; Belanger, A.; Cusan, L.; Gomez, J.L.; Candas, B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 1997, 82, 2396-2402.
20. Webb, S.J.; Geoghegan, T.E.; Prough, R.A.; Miller, K.K.M. The biological actions of dehydroepiandrosterone involve multiple receptors. Drug Metab. Rev., 2006, 38, 89-116.
21. Labrie, F.; Luu-The, V.; Belanger, A.; Lin, S.X.; Simard, J.; Pelletier, G.; Labrie, C. Is dehydroepiandrosterone a hormone? J. Endocrinol., 2005, 187, 169-196.
22. Prough, R.A.; Webb, S.J.; Wu, H.G.; Lapenson, D.P.; Waxman, D.J. Induction of microsomal and peroxisomal enzymes by dehydroepiandrosterone and its metabolite in rats. Cancer Res., 1994, 54, 2878-2886.
23. Jones, S.A.; Moore, L.B.; Shenk, J.L.; Wisely, G.B.; Hamilton, G.A.; McKee, D.D.; Tomkinson, N.C.O.; LeCluyse, E.L.; Lambert, M.H.; Willson, T.M.; Kliewer, S.A.; Moore, J.T. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol., 2000, 14, 27-39.
24. Ripp, S.L.; Fitzpatrick, J.L.; Peters, J.M.; Prough, R.A. Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab. Dispos., 2002, 30, 570-575.
25. Kcombining double acute accenthalmy, K.; Tamási, V.; Kóbori, L.; Sárváry, E.; Pascussi, J.-M.; Porrogi, P.; Rozman, D.; Prough, R.A.; Meyer, U.A.; Monostory, K. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab. Dispos., 2007, 35, 1495-1501.
26. Lu, C.; Li, A.P. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem.-Biol. Interact., 2001, 134, 271-281.
27. Luo, G.; Cunningham, M.; Kim, S.; Burn, T.; Lin, J.; Sinz, M.; Hamilton, G.; Rizzo, C.; Jolley, S.; Gilbert, D.; Downey, A.; Mudra, D.; Graham, R.; Carroll, K.; Xie, J.; Madan, A.; Parkinson, P.; Christ, D.; Selling, B.; Lecluyse, E.; Gan, L.-S. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos., 2002, 30, 795-804.
28. Chen, F.; Knecht, K.; Birzin, E.; Fisher, J.; Wilkinson, H.; Mojena, M.; Moreno, C.T.; Schmidt, A.; Harada, S.; Freedman, L.P.; Reszka, A.A. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology, 2005, 146, 4568-4576.
29. Assem, M.; Schuetz, E.G.; Leggas, M.; Sun, D.; Yasuda, K.; Reid, G.; Zelcer, N.; Adachi, M.; Strom, S.; Evans, R.M.; Moore, D.D.; Borst, P.; Schuetz, J.D. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem., 2004, 279, 22250-22257.
30. Min, G.; Kim, H.; Bae, Y.; Petz, L.; Kemper, J.K. Inhibitory crosstalk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). J. Biol. Chem., 2002, 277, 34626-34633.
31. Pascussi, J.-M.; Drocourt, L.; Gerbal-Chaloin, S.; Fabre, J.-M.; Maurel, P.; Vilarem, M.-J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem., 2001, 268, 6346-6358.
32. Barker, E.V.; Hume, R.; Hallas, A.; Coughtrie, M.W.H. Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes. Endocrinology, 1994, 134, 982-989.
33. Sinclair, P.A.; Gilmore, W.J.; Lin, Z.; Lou, Y.; Squires, E.J. Molecular cloning and regulation of porcine SULT2A1: relationship between SULT2A1 expression and sulfoconjugation of androstenone. J. Mol. Endocrinol., 2006, 36, 301-311.
34. Duanmu, Z.; Locke, D.; Smigelski, J.; Wu, W.; Dahn, M.S.; Falany, C.N.; Kocarek, T.A.; Runge-Morris, M. Effects of dexamethasone on aryl (Sult1A1)- and hydroxysteroid (Sult2A1)-sulfortransferase gene expression in primary cultured human hepatocytes. Drug Metab. Dispos., 2002, 30, 997-1004.
35. Coughtrie, M.W.H. Sulfation through the looking glass-recent advances in sulfotransferase research for the curious. Pharmacogenomics J., 2002, 2, 297-308.
36. Bayliss, K.M.; Skett, P. In: Human Cell Culture Protocols Isolation and culture of human hepatocytes; Jones, G.E. Ed.; Humana Press: Totowa, 1996; pp. 369-390.
37. Ferrini, J.-B.; Ourlin, J.C.; Pichard, L.; Fabre, G.; Maurel, P. In Cytochrome P450 Protocols Human hepatocyte culture; Phillips, I.R.; Shephard, E.A. Eds.; Humana Press: Totowa, 1998; pp. 341-352.